Baseline MD Anderson symptom inventory score is strongly associated with patient-reported acute and late toxicity following (chemo) radiotherapy for head and neck cancers
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractAims: Patient-reported outcomes measures (PROMs) are an increasingly recognised end point of radiotherapy studies. We hypothesised that the baseline PROMs score is the strongest predictor for acute and late scores after treatment. We assessed the strength of association of baseline MD Anderson Symptom Inventory (MDASI) scores, alongside other known factors for patient- or clinician-reported toxicity, with acute (6-week) and late (12-month) scores in head and neck cancer (HNC) patients following (chemo)radiotherapy. Materials and methods: This was a retrospective analysis of longitudinal MDASI scores for 247 patients receiving (chemo)radiotherapy for HNC via multivariable linear regression. The factors investigated were: baseline symptom score, age, sex, concurrent chemotherapy, disease stage, radiotherapy fractionation, prior definitive surgery and performance status. Patients with a baseline score >4 in any item were defined as symptomatic in that category. Results: Patients rated symptomatic for an MDASI item pre-treatment on average reported statistically (P < 0.0005) and clinically (>-1.5) significant reductions in scores 6 weeks and 12 months after (chemo)radiotherapy for all considered sub-items except taste, dryness of mouth and problems with teeth. Conversely patients asymptomatic at baseline reported a worsening of scores at both time points. Other investigated factors showed little association with changes in MDASI scores following treatment. Conclusions: Our data show that baseline MDASI scores are strongly associated with patient-reported toxicity 6 weeks and 12 months after (chemo)radiotherapy for HNC. Patients who are symptomatic at baseline can experience an early and durable benefit from treatment. This finding can inform discussions with patients before therapy and has implications for use of PROMs scores for the assessment of toxicity in randomised trials.
CitationBarker CL, Price GJ, Lee LW, McPartlin A. Baseline MD Anderson Symptom Inventory Score is Strongly Associated With Patient-reported Acute and Late Toxicity Following (Chemo) Radiotherapy for Head and Neck Cancers. Clinical Oncology. Elsevier BV; 2022.
- Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.
- Authors: Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM, Phan J, Frank SJ, Hanna EY, Lu C, Cleeland CS, Rosenthal DI, Gunn GB
- Issue date: 2014 Oct
- Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers.
- Authors: Ren J, Pang W, Hueniken K, Haddad G, Hope A, Huang SH, Spreafico A, Hansen AR, Perez-Ordonez B, Goldstein DP, Bratman SV, Zhang W, Zhao Y, Xu W, de Almeida JR, Liu G
- Issue date: 2022 Feb 1
- The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.
- Authors: Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, Lewin JS, Ang KK, Kies MS, Gning I, Wang XS, Cleeland CS
- Issue date: 2008 Dec 1
- M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy ± systemic therapy - A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
- Authors: Viganò A, De Felice F, Iacovelli NA, Alterio D, Facchinetti N, Oneta O, Bacigalupo A, Tornari E, Ursino S, Paiar F, Caspiani O, Di Rito A, Musio D, Bossi P, Steca P, Jereczek-Fossa BA, Greco A, Orlandi E
- Issue date: 2021 Apr
- Global quality of life during the acute toxicity phase of multimodality treatment for patients with head and neck cancer: can we identify patients most at risk of profound quality of life decline?
- Authors: Tribius S, Reemts E, Prosch C, Raguse M, Petersen C, Kruell A, Singer S, Bergelt C
- Issue date: 2012 Sep